181 related articles for article (PubMed ID: 12869512)
1. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.
Siegel S; Wagner A; Kabelitz D; Marget M; Coggin J; Barsoum A; Rohrer J; Schmitz N; Zeis M
Blood; 2003 Dec; 102(13):4416-23. PubMed ID: 12869512
[TBL] [Abstract][Full Text] [Related]
2. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
[TBL] [Abstract][Full Text] [Related]
3. 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers.
Coggin JH; Barsoum AL; Rohrer JW
Anticancer Res; 1999; 19(6C):5535-42. PubMed ID: 10697612
[TBL] [Abstract][Full Text] [Related]
4. Identification of oncofetal antigen/immature laminin receptor protein epitopes that activate BALB/c mouse OFA/iLRP-specific effector and regulatory T cell clones.
Rohrer JW; Barsoum AL; Coggin JH
J Immunol; 2006 Mar; 176(5):2844-56. PubMed ID: 16493041
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity.
Biragyn A; Schiavo R; Olkhanud P; Sumitomo K; King A; McCain M; Indig FE; Almanzar G; Baatar D
J Immunol; 2007 Jul; 179(2):1381-8. PubMed ID: 17617631
[TBL] [Abstract][Full Text] [Related]
6. Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein.
Barsoum AL; Liu B; Rohrer JW; Coggin JH; Tucker JA; Pannell LK; Schwarzenberger PO
Biomaterials; 2009 Jun; 30(17):3091-9. PubMed ID: 19268360
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies specific for oncofetal antigen--immature laminin receptor protein: Effects on tumor growth and spread in two murine models.
McClintock SD; Warner RL; Ali S; Chekuri A; Dame MK; Attili D; Knibbs RK; Aslam MN; Sinkule J; Morgan AC; Barsoum A; Smith LB; Beer DG; Johnson KJ; Varani J
Cancer Biol Ther; 2015; 16(5):724-32. PubMed ID: 25799942
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based vaccines in patients with hematological malignancies.
Brugger W; Schneider A; Schammann T; Dill P; Grünebach F; Bühring HJ; Kanz L; Brossart P
Ann N Y Acad Sci; 2001 Jun; 938():359-62; discussion 362-3. PubMed ID: 11458523
[TBL] [Abstract][Full Text] [Related]
9. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
[TBL] [Abstract][Full Text] [Related]
10. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.
Mohamed YS; Dunnion D; Teobald I; Walewska R; Browning MJ
Immunobiology; 2012 Jul; 217(7):719-29. PubMed ID: 22305004
[TBL] [Abstract][Full Text] [Related]
11. Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.
Wu L; Zhang H; Jiang Y; Gallo RC; Cheng H
Proc Natl Acad Sci U S A; 2018 May; 115(19):E4453-E4462. PubMed ID: 29674449
[TBL] [Abstract][Full Text] [Related]
12. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.
Schmidt SM; Schag K; Müller MR; Weinschenk T; Appel S; Schoor O; Weck MM; Grünebach F; Kanz L; Stevanovic S; Rammensee HG; Brossart P
Cancer Res; 2004 Feb; 64(3):1164-70. PubMed ID: 14871853
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer.
Lee HJ; Hong CY; Jin CJ; Kim MH; Lee YK; Nguyen-Pham TN; Lee H; Park BC; Chung IJ; Kim HJ; Lee JJ
Cell Mol Immunol; 2012 Mar; 9(2):175-83. PubMed ID: 22231555
[TBL] [Abstract][Full Text] [Related]
15. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
17. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
[TBL] [Abstract][Full Text] [Related]
18. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.
Zeis M; Siegel S; Wagner A; Schmitz M; Marget M; Kühl-Burmeister R; Adamzik I; Kabelitz D; Dreger P; Schmitz N; Heiser A
J Immunol; 2003 Jun; 170(11):5391-7. PubMed ID: 12759413
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
[TBL] [Abstract][Full Text] [Related]
20. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
